The Hormonal Profile of Norethindrone Acetate: Rationale for Add-Back Therapy With Gonadotropin-Releasing Hormone Agonists in Women With Endometriosis

@article{Chwalisz2012TheHP,
  title={The Hormonal Profile of Norethindrone Acetate: Rationale for Add-Back Therapy With Gonadotropin-Releasing Hormone Agonists in Women With Endometriosis},
  author={K. Chwalisz and E. Surrey and F. Stanczyk},
  journal={Reproductive Sciences},
  year={2012},
  volume={19},
  pages={563 - 571}
}
  • K. Chwalisz, E. Surrey, F. Stanczyk
  • Published 2012
  • Medicine
  • Reproductive Sciences
  • Gonadotropin-releasing hormone agonists (GnRHa) are an effective treatment of endometriosis-associated pelvic pain. The use of hormonal add-back therapy can alleviate the hypoestrogenic symptoms associated with GnRHa therapy, while preserving therapeutic efficacy. Norethindrone acetate (NETA) is a unique progestin that has both estrogenic and androgenic properties and is effective as an add-back regimen without estrogen supplementation. Through its estrogenic activity, NETA exerts beneficial… CONTINUE READING
    33 Citations
    Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis
    • 1
    Advances in pharmacotherapy for treating endometriosis
    • 22
    Oral and depot progestin therapy for endometriosis: towards a personalized medicine
    • 8
    • PDF
    Medical treatment of endometriosis-related pain.
    • 36
    • PDF

    References

    SHOWING 1-10 OF 91 REFERENCES
    Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
    • E. Surrey
    • Medicine
    • Current opinion in obstetrics & gynecology
    • 2010
    • 44
    The role of add-back therapy in the United States.
    • 9
    Add-back therapy use and its impact on LA persistence in patients with endometriosis
    • 19
    Hormone treatment of endometriosis: the estrogen threshold hypothesis.
    • R. Barbieri
    • Medicine
    • American journal of obstetrics and gynecology
    • 1992
    • 127
    Gonadotropin-releasing hormone agonists for endometriosis.
    • 21